Predicting outcome and tailoring treatment in high-grade gliomas

Lancet Oncology

Volumn 4, Issue 5, 2003, Pages 269-270

  Bredel, Markus ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR;

ADULT; AGE; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL PRACTICE; CYTOGENETICS; DISEASE COURSE; GENOTYPE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; NERVOUS SYSTEM FUNCTION; NOTE; OLIGODENDROGLIOMA; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0038392754     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01072-6     Document Type: Note

References (5)

1. Gupta T, Sarin R. Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care. Lancet Oncol 2002; 3: 557-64.
2. MRC Working Party. A study on the effect of misonidazole in conjunction with radiotherapy for the treatment of grade 3 and 4 astrocytomas. Br J Radiol 1983; 56: 673-82.
3. MRC Brain Tumour Working Party. Prognostic factors for high-grade malignant gliomas: development of a prognostic index. J Neurooncol 1990; 9: 47-55.
4. Efficace F, Bottomley A. Assessing HRQOL: a neglected issue for high-grade glioma. Lancet Oncol 2003; 4: 11-12.
5. Louis DN, Pomeroy SL, Cairncross JG. Focus on central nervous system neoplasia. Cancer Cell 2002; 1: 125-28.